Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for People

Industry Veteran Haggar To Lead Private Equity-Backed Zentiva From Next Month

Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.

Appointments Europe

Akorn’s Chief Operating Officer Heads For The Exit Days Into Doug Boothe’s Tenure

A month after a court ruled that Fresenius Kabi’s decision to terminate its merger with Akorn was legal and proper, Akorn’s COO has agreed to resign the position, six days after Doug Boothe officially replaced Raj Rai as Akorn’s new president and CEO.

Strategy Leadership

Coherus Confirms Udenyca Launch And Brings In Chief Medical Officer

The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.

Launches Biosimilars

Akorn Selects Doug Boothe As CEO

Around two weeks after announcing that the firm was seeking a new CEO, Akorn has chosen former president of Impax’ generics division, Doug Boothe, to lead the US firm.

United States Appointments

Narayan is value-added chair

European off-patent industry association Medicines for Europe has appointed Arun Narayan as chair of its value-added medicines segment, taking over from Umberto Comberiati.


Kaczmarek will lead G&W Dermatology

Private-equity firm Avista Capital Partners has struck a deal to acquire the extended topicals and dermatology business of privately-owned US company G&W Laboratories, which it plans to operate as G&W Dermatology under new chief executive officer Walt Kaczmarek.

See All